Literature DB >> 2239925

Recurrent disseminated intravascular coagulation and fulminant intra hepatic thrombosis in a patient with the anti-phospholipid syndrome.

J Stinson1, G Tomkin, G McDonald, F Jackson, M Harrison, A Murray, C Feighery, J Jackson.   

Abstract

We describe a patient with the lupus anti-coagulant who had recurrent episodes, over a 2 year period, of a severe and disseminated intravascular coagulopathy. This patient also had positive serological assays for syphilis and anti-cardiolipin antibodies. Associated with the coagulopathy were co-expressed episodes of liver disease, ultimately terminating in fulminant liver failure. At autopsy the features were characteristic of the Budd-Chiari syndrome. This is the first report to document how consumptive coagulopathy may present as a dominant feature of the anti-phospholipid syndrome. It also clearly describes an immune mediated thrombotic mechanism as a cause of hepatic veno-occlusive disorders. Furthermore, this case highlights the varied clinical spectrum of the anti-phospholipid syndrome and suggests that a high index of suspicion is required to ensure its diagnosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239925     DOI: 10.1002/ajh.2830350413

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Recognizing antiphospholipid syndrome. Case report: misdiagnosis delayed treatment.

Authors:  P Kirk; J A Moran
Journal:  Can Fam Physician       Date:  1996-02       Impact factor: 3.275

2.  Cerebral venous thrombosis and chronic active hepatitis as part of the antiphospholipid syndrome.

Authors:  A Kesler; I S Pomeranz; M Huberman; B Novis; E Kott
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

Review 3.  Budd-chiari syndrome causing acute liver failure: A multicenter case series.

Authors:  Justin Parekh; Vlad M Matei; Alejandro Canas-Coto; Daniel Friedman; William M Lee
Journal:  Liver Transpl       Date:  2017-02       Impact factor: 5.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.